TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02684214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Plus +
Description: Families will receive 6 monthly newsletters and meet with a BHC at the clinic for 30 minutes during months 1, 3, and 5. Child height and weight will be taken. Families will receive feedback about growth and the weight status of their child. The session materials will be reviewed and behavioral parenting strategies will be encouraged to aid with changing two dietary and two leisure-time activity (energy balance) behaviors of the child. The caretaker will also change the same energy balance behaviors as the child, as adult caretakers can then model healthy behaviors. The caretaker and child will be encouraged to change and self-monitor energy balance behaviors with the use of the picture-based diaries. During months 2, 4, and 6, BHCs will complete a 20-minute phone call with the caretaker. Caretakers will be asked to measure the height and weight of their child, calculate BMI and plot it on the BMI-for-age growth chart prior to the call. The BHC will provide feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Plus +
Description: Families will receive 6 monthly newsletters and meet with a BHC at the clinic for 30 minutes during months 1, 3, and 5. Child height and weight will be taken. Families will receive feedback about growth and the weight status of their child. The session materials will be reviewed and behavioral parenting strategies will be encouraged to aid with changing two dietary and two leisure-time activity (energy balance) behaviors of the child. The caretaker will also change the same energy balance behaviors as the child, as adult caretakers can then model healthy behaviors. The caretaker and child will be encouraged to change and self-monitor energy balance behaviors with the use of the picture-based diaries. During months 2, 4, and 6, BHCs will complete a 20-minute phone call with the caretaker. Caretakers will be asked to measure the height and weight of their child, calculate BMI and plot it on the BMI-for-age growth chart prior to the call. The BHC will provide feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Plus -
Description: This condition will be identical to PP+ except that caretakers will not receive any energy balance behavior goals. Additionally, the caretaker will not self-monitor energy balance behaviors. The focus will be on all other behavioral parenting strategies to assist the child with making changes in the targeted behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Plus -
Description: This condition will be identical to PP+ except that caretakers will not receive any energy balance behavior goals. Additionally, the caretaker will not self-monitor energy balance behaviors. The focus will be on all other behavioral parenting strategies to assist the child with making changes in the targeted behaviors.
Study: NCT00951730

Intervention type: OTHER
Intervention: Polysomnography
Description: Polysomnography is the method of choice for the diagnosis of sleep apnea. This test lasts for one night in hospital.
Study: NCT04623242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Subcutaneously every 4 weeks at escalating doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solanezumab
Description: Intravenous infusion every 4 weeks at escalating doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo (Gantenerumab)
Description: Subcutaneous injection of placebo every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo (Solanezumab)
Description: Intravenous infusion of placebo every 4 weeks
Study: NCT04325542

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HBSAg (sure screen test)
Description: Diagnostic test for Hepatitis B
Study: NCT01125280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative treatment versus surgical treatment
Description: Conservative treatment: starving, nasogastric tube Surgical treatment: open laparotomy, adhesiolysis, with or without small bowel resection
Study: NCT03770065

Intervention type: DEVICE
Intervention: VML-0001
Description: Medical device

Intervention type: DEVICE
Intervention: VML-0001
Description: Medical device
Study: NCT02326805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rilimogene Galvacirepvec
Description: Given SC
Study: NCT03300466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GP0045
Description: Hyaluronic acid gel

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Hyaluronic acid gel
Study: NCT02897895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: levels of CNI in whole blood

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: levels of CNI in whole blood

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Calcineurin activity (CN-a) in peripheral blood mononuclear cells (PBMCs)
Study: NCT03343132

Intervention type: BEHAVIORAL
Intervention: Standard locomotor therapy
Description: Typical clinical therapy.
Study: NCT02797236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SF2a-TT15 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SF2a-TT15 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SF2a-TT15 vaccine + adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SF2a-TT15 vaccine + adjuvant

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + adjuvant
Study: NCT03847987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7017773 Phase I Capsule
Description: Participants will receive 1 single oral dose of RO7017773 Phase I Capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7017773 Phase II Tablet Unflavored
Description: Participants will receive 3 single oral doses of unflavored RO7017773 Phase II tablet during Part 1, and 1 single oral dose of unflavored RO7017773 Phase II tablet during Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7017773 Phase II Tablet Unflavored
Description: Participants will receive 3 single oral doses of unflavored RO7017773 Phase II tablet during Part 1, and 1 single oral dose of unflavored RO7017773 Phase II tablet during Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7017773 Phase II Tablet Sweetened/Flavored
Description: Participants will receive 1 single oral dose of sweetened/flavored RO7017773 Phase II tablet during Part 2.
Study: NCT03960281

Intervention type: OTHER
Intervention: Regular dental examination
Description: Regular dental examination, and the patient will be asked to fill a questionnaire
Study: NCT02472132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POC US
Description: Use of point of care ultrasound in insertion of CVC
Study: NCT04222595

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluenz Tetra nasal spray suspension
Description: Prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluenz Tetra nasal spray suspension
Description: Prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluenz Tetra nasal spray suspension
Description: Prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. Single dose vaccine, administered as a nasal spray (0.2 ml administered as 0.1 ml per nostril).
Study: NCT03824860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Participants will attend at least one group class per week (in-person or Zoom) and practice one self-guided yoga video class at home on their own per week, over eight weeks~Participants may choose to attend Flow Yoga and/or Chair Flow Yoga classes. These classes will be videotaped and made available to participants electronically.~Classes consist of:~* guided breathing exercises,~* upper and lower extremity stretching~* structured postures and movements to improve balance and strength
Study: NCT01858181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ocaratuzumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ocaratuzumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ocaratuzumab
Study: NCT03253146

Intervention type: DIAGNOSTIC_TEST
Intervention: VIM detection
Description: VIM expression in serum and lymphocytes detection

Intervention type: DIAGNOSTIC_TEST
Intervention: VIM detection
Description: VIM expression in serum and lymphocytes detection
Study: NCT04312009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan; 50 mg daily; oral administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration
Study: NCT03146572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit Down and Play
Description: Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Handout
Description: Handout providing written descriptions of strategies to encourage positive parenting behaviors
Study: NCT00179309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 35 mg/m\^2 intravenous 30-60 minutes once a week for 3 consecutive weeks with 1 week off drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 35 mg/m\^2 intravenous 30-60 minutes once a week for 3 consecutive weeks with 1 week off drug.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PANVAC-V
Description: 2 x 10\^8 PFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PANVAC-F
Description: 1 x 10\^9 PFU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given subcutaneously under the skin, usually in the thigh on the day of vaccination and daily for the next 3 days.
Study: NCT03714945

Intervention type: OTHER
Intervention: No intervention
Description: No intervention is required as this study is observational.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention is required as this study is observational.
Study: NCT01902966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Starting dose: 20 mg is taken by mouth twice a day (40 mg/day).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diary
Description: Patients record study medication taken each day in a pill diary. Relaxation diary completed after listening to audio sessions twice a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Audio Recording
Description: Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed at baseline, 2 months, and 4 months.
Study: NCT02777216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ConfidenHT system
Description: ConfidenHT Medical system
Study: NCT03044340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: impedance measurement and pain evaluation
Description: Measurement of chlorine ions impedance by SUDOSCAN and pain due to temperature evaluation with THERMOTEST
Study: NCT01262521

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary nitrate
Description: 150 ml tab water with 150 umol/kg sodium-nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 150 ml Chapelle mineral water
Study: NCT02868242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: Tablet(s) administered orally once daily
Study: NCT00719927

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comadres Weight Loss Pilot Program
Description: The first condition will consist of women participating with a female friend (comadre), while the second condition will consist of women participating without a support partner.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comadres Weight Loss Pilot Program
Description: The first condition will consist of women participating with a female friend (comadre), while the second condition will consist of women participating without a support partner.
Study: NCT02098174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-3180
Description: MP-3180 (1 µmol/kg or 0.372 mg/kg) (fluorescent tracer agent) was administered by IV injection (2.5 mL to 3.5 mL for participant weights of 70 kg to 91 kg) over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iohexol comparator
Description: Iohexol (Omnipaque 300, 5 mL) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
Study: NCT03193398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTRX-246040 oral capsule(s)
Description: BTRX-246040 administered once daily to patients with MDD for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule(s)
Description: administered once daily to patients with MDD for 8 weeks
Study: NCT03232476

Intervention type: DEVICE
Group type: OTHER
Intervention: Upper extremity voluntary loading
Description: Subjects who are prescribed teriparatide by their healthcare provider may enroll in this study. The study intervention consists of loading one upper extremity. Subjects will be trained on how to perform the upper extremity exercises at home. Subjects will be expected to perform the exercises 3 days per week using one arm, with each session consisting of 100 loading cycles lasting a total of approximately 2 minutes each day.
Study: NCT01148446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/mq IV, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/mq IV, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/mq IV, day1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1,4 mg/mq (max 2 mg)IV, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 75 mg/mq IV, days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg/mq IV/PO, days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 50 mg/mq IV, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: 5 mg/mq IV, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/mq IV, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/mq IV, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 300 µg tot., SC; days 7-11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 300 µg tot., SC; days 7-11
Study: NCT03608943

Intervention type: OTHER
Intervention: There is no specific intervention other than an individual changing their treatment as part of their usual care
Description: There is no specific intervention other than an individual changing their treatment as part of their usual care
Study: NCT05396742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Solution for infusion or injection, as applicable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Solution for infusion or injection, as applicable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Solution for infusion or injection, as applicable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Solution for infusion or injection, as applicable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Solution for infusion or injection, as applicable

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Solution for infusion
Study: NCT04110847

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JING CEIH SHERN YUAN EXTRACT PILL
Description: Oral use, 3#BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JING CEIH SHERN YUAN EXTRACT PILL
Description: Oral use, 3#BID
Study: NCT02554539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial fluid aspiration
Description: Patient will undergo a biopsy to aspirate endometrial fluid from the uterine cavity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial fluid aspiration
Description: Patient will undergo a biopsy to aspirate endometrial fluid from the uterine cavity
Study: NCT04079270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Description: The diet recommendations will be provided by a certified dietitian. Participants will be asked to document their food intake and daily activities including exercise and sleep using a dedicated smartphone app throughout the intervention period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition intervention
Description: The diet recommendations will be provided by a certified dietitian. Participants will be asked to document their food intake and daily activities including exercise and sleep using a dedicated smartphone app throughout the intervention period.
Study: NCT04519892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PDRC
Description: Personalized depression risk communication.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PDRC
Description: Personalized depression risk communication.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coach guidance
Description: Coaching service to guide the understanding of PDRC and answer questions.
Study: NCT03431571

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ReLEx SMILE
Description: the VisuMax femtosecond laser is used to cut a thin layer of corneal tissue that is removed through a small cut in the cornea
Study: NCT04479566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate 250 MG
Description: Patients undergoing video assisted thoracic surgery during the morning will take 250mg lithium carbonate 6 hours after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Carbonate 500 MG
Description: Patients undergoing video assisted thoracic surgery during the morning will take calcium carbonate 500mg 6 hours after surgery.
Study: NCT00783094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5 mg
Description: oral, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Description: oral, daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, daily
Study: NCT01941407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin: 1,23mg/m² d1, d8, IV Bevacizumab: 15mg/kg d1, IV
Study: NCT03981783

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best available care (BAC)
Description: Eligible patients are assigned to a standard pulmonary rehabilitation program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (TH)
Description: Eligible patients are assigned to a pulmonary telerehabilitation program
Study: NCT03840538

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic Product - Cap
Description: probiotic capsule complex composed of L.acidophilus, L. bulgaricus, Streptococcus thermophilus, and Bifidobacterium bifidus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Product - Cap
Description: probiotic capsule complex composed of L.acidophilus, L. bulgaricus, Streptococcus thermophilus, and Bifidobacterium bifidus
Study: NCT02869386

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STEMO
Description: STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure Management (choice of drug at discretion of treating physician), use telemedicine for further expertise as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regular care
Description: A regular ambulance, the comparator intervention, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
Study: NCT02517775

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry 320
Description: Dietary Supplement: Cranberry beverage with 320 mg of (poly)phenols Acute intake of 500 mL (1x daily)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry 640
Description: Dietary Supplement: Cranberry beverage with 640 mg of (poly)phenols Acute intake of 500 mL (1x daily)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry 960
Description: Dietary Supplement: Cranberry beverage with 960 mg of (poly)phenols Acute intake of 500 mL (1x daily)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry 1280
Description: Dietary Supplement: Cranberry beverage with 1280 mg of (poly)phenols Acute intake of 500 mL (1x daily)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry 1600
Description: Dietary Supplement: Cranberry beverage with 1600 mg of (poly)phenols Acute intake of 500 mL (1x daily)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cranberry deprived supplement
Description: Cranberry deprived supplement Acute intake of 500 mL (1x daily)